Caidya (dMed) private stock trade

Caidya (dMed)

Legal NamedMed Biopharmaceutical Co., Ltd
HeadquartersShanghai
SectorHealthTech

dMed is a leading clinical research organization (CRO) that specializes in providing comprehensive services for the development of innovative drugs and medical devices. The company offers a wide range of solutions, including clinical trial management, regulatory consulting, data management, biostatistics, and medical writing, to support clients throughout the entire drug development lifecycle. dMed's expertise lies in its experienced team of professionals, who possess deep domain knowledge and a strong track record of success in the pharmaceutical and biotech industries. By leveraging advanced technologies and industry best practices, dMed aims to accelerate the development of new therapies and improve patient outcomes by delivering high-quality, cost-effective solutions that meet the rigorous regulatory standards and requirements of global health authorities.

Learn more about Caidya (dMed) IPO

Secondary Pricing Information

$ .star in blue circleZX Index Value | Get ZXData access
--ZX Index Value VS Reported Marks
pricing graph placeholder
star in blue circleTo view Pre-IPO pricing data for Caidya (dMed), log in to ZXData or contact us to request access.
<

Secondary Volume Information

$ .M star in blue circleAggregate Volume | Get ZXData access
volume graph placeholder
star in blue circleTo view Pre-IPO volume data for Caidya (dMed), log in to ZXData or contact us to request access.

Similar Companies

View More

ZXData is a leading provider of real-time secondary data on private companies. ZXData's dataset incoroporates closed trades with 20bn+ in volume. In addition, it incorporates $200bn+ of buy/sell prices and $56bn+ of reported marks to provide private market investors, trading desks, lenders, and companies with unprecedented market intelligence on private companies.

Disclaimer

This report is provided for informational purposes only and does not constitute a recommendation or solicitation to buy or sell any financial instrument or to participate in any trading strategy and should not be construed as such. The values shown in this report are not indicative price quotations. This report does not constitute investment advice, nor does this report constitute a "research report" as defined by FINRA Rule 2241 or a "debt research report" as defined by FINRA Rule 2242.

The ZXData and the information contained in this report, some of which have been obtained from third-party sources, are provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. Neither Zanbato Inc. (“Zanbato”) nor its affiliates guarantee the accuracy or completeness of the data contained in this report, or its computation and compilation.

The ZXData and this report constitute Zanbato’s valuable intellectual property. You are expressly prohibited from copying, modifying, transmitting or redistributing the ZXData or this report without Zanbato’s prior written consent.